GoAI
Get started
Human Health Holdings Limited logo

Human Health Holdings Limited

1419.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.73

−HK$0.005 · -0.68%

Aug 24, 2:27 PM HKT

1419.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Operating as an investment holding company, Human Health Holdings Limited delivers a comprehensive range of healthcare services across Hong Kong. Its primary care offerings encompass a wide array of services such as routine consultations, diagnostic testing, preventive health programs, minor medical interventions, immunizations, comprehensive physical examinations, health education, and occupational health guidance. Additionally, they provide Traditional Chinese Medicine, work injury assessments, telemedicine, COVID-19 specific services, community outreach, and various health-related products and solutions. The company extends its expertise to numerous specialized medical fields, including general surgery, orthopedics and traumatology, ophthalmology, otorhinolaryngology, pediatrics, obstetrics and gynecology, gastroenterology and hepatology, respiratory medicine, cardiology, pediatric surgery, dermatology and venereology, psychiatry, radiology, urology, nephrology, neurosurgery, anaesthesiology, and oncology. Complementing these are allied health services like physiotherapy, clinical psychology, medical aesthetics, nutritional counseling, health and wellness programs, endoscopy, and advanced medical diagnostics. Furthermore, a full spectrum of dental care is available, ranging from general dentistry, dental implants (including 3D guided surgery), crowns, bridges, and periodontal treatments, to prosthodontics, oral surgery, orthodontics, and endodontics. Cosmetic options like teeth whitening, veneers, and laser dentistry are also provided, alongside advanced oral and maxillofacial surgery, CAD/CAM technology, panoramic radiography, and cone-beam CT scans. Beyond direct patient care, the company manages agreements for healthcare practitioners and offers essential medical imaging services. Established in 1997 and headquartered in Kowloon, Hong Kong, Human Health Holdings Limited maintained a network of 58 medical centers and 103 service points as of June 30, 2021. It operates as a subsidiary of Treasure Group Global Limited.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
HK
CEO
Kin Ping Chan
Listed since
Apr 1, 2016
Employees
544

Market position

Day range

Current HK$0.73

52-week range

Current HK$0.73

Open
HK$0.735
Previous close
HK$0.735
Volume
6K
0.16× average
Average volume
38.29K
Average daily volume
Market cap
277.07M HKD
Beta
0.05
Market reference 1
50-day average
HK$0.7533
-3.09% below average
200-day average
HK$0.7981
-8.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
11.44M HKD
P/E (TTM)
9.97×
P/B (TTM)
0.35×
P/S (TTM)
0.41×
EV / EBITDA
0.22×
Earnings yield
8.31%
Free cash flow yield
28.26%
Dividend yield
4.11%

Profitability & efficiency

Gross margin
40.87%
Operating margin
10.54%
Net margin
4.14%
Return on equity
3.37%
Return on assets
2.46%
Return on invested capital
9.44%

Financial health

Debt / equity
0.22×
Current ratio
2.88×
Altman Z-score
3.28
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%42%20%-3%Gross margin, FY2020: 57.54%Gross margin, FY2021: 58.81%Gross margin, FY2022: 59.22%Gross margin, FY2023: 45.67%Gross margin, FY2024: 46.02%Operating margin, FY2020: 22.70%Operating margin, FY2021: 38.23%Operating margin, FY2022: 30.65%Operating margin, FY2023: 3.04%Operating margin, FY2024: 15.38%Net margin, FY2020: 22.06%Net margin, FY2021: 33.46%Net margin, FY2022: 18.05%Net margin, FY2023: 4.09%Net margin, FY2024: 4.09%FY2020FY2021FY2022FY2023FY2024
Gross margin FY2020 57.54%. Gross margin FY2021 58.81%. Gross margin FY2022 59.22%. Gross margin FY2023 45.67%. Gross margin FY2024 46.02%. Operating margin FY2020 22.70%. Operating margin FY2021 38.23%. Operating margin FY2022 30.65%. Operating margin FY2023 3.04%. Operating margin FY2024 15.38%. Net margin FY2020 22.06%. Net margin FY2021 33.46%. Net margin FY2022 18.05%. Net margin FY2023 4.09%. Net margin FY2024 4.09%.

Income trends

Revenue

644.43M HKD+9.07%

Operating income

99.11M HKD+452.34%

Net income

26.34M HKD+8.88%
Income trends across reported periods1.23B HKD790.64M HKD349.1M HKD−92.44M HKDRevenue, FY2020: 654.71M HKDRevenue, FY2021: 1.12B HKDRevenue, FY2022: 1B HKDRevenue, FY2023: 590.82M HKDRevenue, FY2024: 644.43M HKDOperating income, FY2020: 148.64M HKDOperating income, FY2021: 428.81M HKDOperating income, FY2022: 307.07M HKDOperating income, FY2023: 17.94M HKDOperating income, FY2024: 99.11M HKDNet income, FY2020: 144.45M HKDNet income, FY2021: 375.31M HKDNet income, FY2022: 180.84M HKDNet income, FY2023: 24.19M HKDNet income, FY2024: 26.34M HKDFY2020FY2021FY2022FY2023FY2024
Revenue FY2020 654.71M HKD. Revenue FY2021 1.12B HKD. Revenue FY2022 1B HKD. Revenue FY2023 590.82M HKD. Revenue FY2024 644.43M HKD. Operating income FY2020 148.64M HKD. Operating income FY2021 428.81M HKD. Operating income FY2022 307.07M HKD. Operating income FY2023 17.94M HKD. Operating income FY2024 99.11M HKD. Net income FY2020 144.45M HKD. Net income FY2021 375.31M HKD. Net income FY2022 180.84M HKD. Net income FY2023 24.19M HKD. Net income FY2024 26.34M HKD.
Metric (HKD)FY2024FY2023FY2022FY2021FY2020
Revenue644.43M HKD590.82M HKD1B HKD1.12B HKD654.71M HKD
Cost of goods sold347.86M HKD320.97M HKD408.51M HKD462.11M HKD278.02M HKD
Gross profit296.57M HKD269.85M HKD593.24M HKD659.69M HKD376.69M HKD
Selling, general, and administrative197.46M HKD183.7M HKD211.37M HKD167.8M HKD163.03M HKD
Operating expenses197.46M HKD183.7M HKD211.37M HKD167.8M HKD163.03M HKD
Interest income12.7M HKD17.15M HKD8.49M HKD199K HKD293K HKD
Interest expense6.55M HKD8.22M HKD8.3M HKD2.93M HKD2.93M HKD
Depreciation and amortization20.92M HKD68.01M HKD74.99M HKD63.07M HKD67.6M HKD
Operating income99.11M HKD17.94M HKD307.07M HKD428.81M HKD148.64M HKD
Net income26.34M HKD24.19M HKD180.84M HKD375.31M HKD144.45M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.05

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.830.450.07-0.31Q4 '21Q2 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q4 '25
Q4 2021, reported Dec 31, 2021: actual 0.238, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual 0.751, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Feb 25, 2023: actual 0.706, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 26, 2023: actual -0.23, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Feb 27, 2024: actual 0.053, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Sep 26, 2024: actual 0.011, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 26, 2025: actual 0.044, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 31, 2025: actual 0.048, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates768.29M598.91M429.53M260.15MQ4 '21No estimateQ2 '22No estimateQ1 '23BeatQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25No estimateQ4 '25No estimate
Q4 2021, reported Dec 31, 2021: actual 388.54M HKD, estimate —, surprise —, Comparison unavailable. Q2 2022, reported Jun 30, 2022: actual 733.25M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Feb 25, 2023: actual 681.27M HKD, estimate 528.1M HKD, surprise +29.00%, Beat. Q3 2023, reported Sep 26, 2023: actual 320.47M HKD, estimate 528.1M HKD, surprise -39.32%, Miss. Q1 2024, reported Feb 27, 2024: actual 295.19M HKD, estimate 528.1M HKD, surprise -44.10%, Miss. Q3 2024, reported Sep 26, 2024: actual 295.63M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 26, 2025: actual 315.79M HKD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Dec 31, 2025: actual 342.35M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.03

2025 complete year-75.0% since 2021

Corporate action history

Dividend

Ex-dividend Dec 15, 2025

HK$0.03

Annual

Record Dec 17, 2025 · Payment Jan 5, 2026

Dividend

Ex-dividend Dec 4, 2024

HK$0.028

Annual

Record Dec 6, 2024 · Payment Dec 30, 2024

Dividend

Ex-dividend Dec 11, 2023

HK$0.16

Annual

Record Dec 12, 2023 · Payment Dec 29, 2023

Dividend

Ex-dividend Dec 6, 2022

HK$0.30

Annual

Record Dec 7, 2022 · Payment Dec 23, 2022

Dividend

Ex-dividend Dec 7, 2021

HK$0.12

Annual

Record Dec 8, 2021 · Payment Dec 28, 2021

Dividend

Ex-dividend Dec 3, 2019

HK$0.03

Annual

Record Dec 4, 2019 · Payment Dec 23, 2019

1419.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 1419.HK

research.disclaimer